Ziltivekimab for atherosclerosis

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 16 Feb 2024: Trial registered, NCT06263244
  2. 3 May 2024: Trial started, NCT06263244
  3. 11 Dec 2025: Trial registered, NCT07276282
  4. 19 Dec 2025: Trial started, NCT07276282

The trials

NCT06263244: Specifying the Anti-inflammatory Effects of Ziltivekimab

State
Completed
Phase
Phase 3
People
40 taking part
Started
3 May 2024
Primary completion
30 Oct 2026
Arms
Ziltivekimab
Results
None posted
  1. 16 Feb 2024: Trial registered
  2. 3 May 2024: Trial started
  3. 30 Oct 2026: Trial completed

NCT07276282: Effects of Ziltivekimab on Coronary Atherosclerotic Burden in Patients With Acute Myocardial Infarction

State
Under way
Phase
Phase 3
People
332 planned
Started
19 Dec 2025
Primary completion
1 Sep 2028
Arms
Ziltivekimab Arm
Results
None posted
  1. 11 Dec 2025: Trial registered
  2. 19 Dec 2025: Trial started

How the status changed

  1. 16 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Ziltivekimab B, Ziltivekimab C.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.